Table 3.
Effects of ABCC2 (G1249A) Polymorphism on the Efflux Activity of Paclitaxel, Docetaxel, Sorafenib, and Doxorubicin in Recombinant LLC-PK1 Monolayers
| LLC-PK1 Cells | Papp (B→A)/Papp (A→B) | |||
|---|---|---|---|---|
| CLT | pDNA3.1 | 1249G | 1249A | |
| Paclitaxel | 0.87±0.07 | 0.81±0.06 | 3.64±0.57** | 12.08±0.69**,## |
| Paclitaxel+MK-571 | 0.96±0.06 | 0.89±0.05 | 1.54±0.07*,† | 1.79±0.10*,† |
| Docetaxel | 1.34±0.16 | 1.47±0.18 | 5.06±0.34** | 4.69±0.41** |
| Docetaxel+MK-571 | 1.46±0.19 | 1.54±0.21 | 2.12±0.24*,† | 1.96±0.26†† |
| Doxorubicin | 0.54±0.06 | 0.67±0.05 | 4.19±0.14** | 13.27±0.24**,## |
| Doxorubicin+MK-571 | 0.65±0.05 | 0.58±0.03 | 3.64±0.24*,† | 3.88±0.29*,† |
Notes: Compared with pcDNA3.1 group, *p<0.05, **p<0.01; compared with 1249G group, ##p<0.01; compared with without inhibitor group, †p<0.05, ††p<0.01.
Abbreviations: CTL, cells untransfected LLC-PK1 cells; pcDNA3.1, transfected with empty vector; 1249G, transfected with 1249G wild-type allele; 1249A, cells transfected with 1249A variant allele.